Health state utilities for beta-thalassemia: a time trade-off study

[1]  Emma L. Smith,et al.  From subject choice to career path: Female STEM graduates in the UK labour market , 2021, Oxford Review of Education.

[2]  E. Balman,et al.  National Institute for Health and Care Excellence (NICE) , 2017, The Grants Register 2022.

[3]  L. Matza,et al.  Health state utilities associated with treatment for transfusion-dependent β-thalassemia , 2019, The European Journal of Health Economics.

[4]  Wed,et al.  August 2019 , 2019, TAPPI Journal.

[5]  I. Huys,et al.  Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review. , 2019, Drug discovery today.

[6]  Elly Stolk,et al.  Overview, Update, and Lessons Learned From the International EQ-5D-5L Valuation Work: Version 2 of the EQ-5D-5L Valuation Protocol. , 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[7]  E. Neufeld,et al.  The Believe Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept in Adult Beta-Thalassemia Patients Who Require Regular Red Blood Cell (RBC) Transfusions , 2018, Blood.

[8]  Elly Stolk,et al.  Evaluation of Split Version and Feedback Module on the Improvement of Time Trade-Off Data. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[9]  Brendan Mulhern,et al.  Valuing health‐related quality of life: An EQ‐5D‐5L value set for England , 2017, Health economics.

[10]  Juan Manuel Ramos-Goñi,et al.  Assessing the Use of a Feedback Module to Model EQ-5D-5L Health States Values in Hong Kong , 2017, The Patient - Patient-Centered Outcomes Research.

[11]  Joanna Coast,et al.  How Qualitative Methods Can be Used to Inform Model Development , 2017, PharmacoEconomics.

[12]  Mark Oppe,et al.  Quality Control Process for EQ-5D-5L Valuation Studies. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[13]  G. Sanders,et al.  Cost-Effectiveness in Health and Medicine , 2016 .

[14]  A. Piga,et al.  Luspatercept Increases Hemoglobin, Decreases Transfusion Burden and Improves Iron Overload in Adults with Beta-Thalassemia , 2016 .

[15]  C. Carcassi,et al.  Mediterranean Journal of Hematology and Infectious Diseases What Unrelated Hematopoietic Stem Cell Transplantation in Thalassemia Taught Us about Transplant Immunogenetics , 2022 .

[16]  F. Dorkoosh,et al.  Health-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in Iran , 2016, International journal of hematology-oncology and stem cell research.

[17]  Karl Claxton,et al.  Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal. , 2016, Health economics.

[18]  I. Papassotiriou,et al.  2017 Clinical trials update in new treatments of β‐thalassemia , 2016, American journal of hematology.

[19]  B. Andersson,et al.  Hematopoietic stem cell transplantation for homozygous β-thalassemia and β-thalassemia/hemoglobin E patients from haploidentical donors , 2016, Bone Marrow Transplantation.

[20]  J. Guest,et al.  Healthcare costs and outcomes of managing β‐thalassemia major over 50 years in the United Kingdom , 2016, Transfusion.

[21]  Mark Oppe,et al.  EuroQol Protocols for Time Trade-Off Valuation of Health Outcomes , 2016, PharmacoEconomics.

[22]  M. Javanbakht,et al.  Comparison of Blood Transfusion Plus Chelation Therapy and Bone Marrow Transplantation in Patients with Β-Thalassemia: Application of SF-36, EQ-5D, and Visual Analogue Scale Measures , 2015, International journal of health policy and management.

[23]  A. Taher,et al.  Guidelines for Diagnosis and Management of Beta-Thalassemia Intermedia , 2014, Pediatric hematology and oncology.

[24]  Mark Oppe,et al.  A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[25]  E. Neufeld,et al.  Relationship among chelator adherence, change in chelators, and quality of life in Thalassemia , 2014, Quality of Life Research.

[26]  E. Neufeld,et al.  Validation and reliability of a disease‐specific quality of life measure (the TranQol) in adults and children with thalassaemia major , 2014, British journal of haematology.

[27]  M. Versteegh,et al.  Time trade-off: one methodology, different methods , 2013, The European Journal of Health Economics.

[28]  Mark Oppe,et al.  Introducing the composite time trade-off: a test of feasibility and face validity , 2013, The European Journal of Health Economics.

[29]  A. Ganser,et al.  Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial , 2012, Anemia.

[30]  C. Pashos,et al.  A cost-effectiveness analysis of using azacitidine vs. decitabine in treating patients with myelodysplastic syndromes , 2012, Journal of medical economics.

[31]  G. Collins,et al.  Prospective assessment of health-related quality of life in pediatric patients with beta-thalassemia following hematopoietic stem cell transplantation. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[32]  E. d’Aloja,et al.  Ethical issues of unrelated hematopoietic stem cell transplantation in adult thalassemia patients , 2011, BMC medical ethics.

[33]  Aki Tsuchiya,et al.  A uniform time trade off method for states better and worse than dead: feasibility study of the 'lead time' approach. , 2011, Health economics.

[34]  J. Brazier,et al.  NICE DSU Technical Support Document 11: Alternatives to EQ-5D for Generating Health State Utility Values [Internet] , 2011 .

[35]  D. Weatherall.  The inherited diseases of hemoglobin are an emerging global health burden. , 2010, Blood.

[36]  Raffaella Origa,et al.  BETA THALASSEMIA , 2018, The Professional Medical Journal.

[37]  Pierre Fenaux,et al.  Valuation of transfusion-free living in MDS: results of health utility interviews with patients , 2009, Health and quality of life outcomes.

[38]  John Brazier,et al.  Mapping SF-36 onto the EQ-5D index: how reliable is the relationship? , 2009, Health and quality of life outcomes.

[39]  I. Proskorovsky,et al.  Iron chelation therapy: Clinical effectiveness, economic burden and quality of life in patients with iron overload , 2008, Advances in therapy.

[40]  J. Karnon,et al.  Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom* , 2008, Current medical research and opinion.

[41]  G. Lucarelli,et al.  Advances in the allogeneic transplantation for thalassemia. , 2008, Blood reviews.

[42]  Lisa S Whiting,et al.  Semi-structured interviews: guidance for novice researchers. , 2008, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[43]  T. Goss,et al.  Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States. , 2006, Cancer control : journal of the Moffitt Cancer Center.

[44]  Angela Robinson,et al.  Exploring challenges to TTO utilities: valuing states worse than dead. , 2006, Health economics.

[45]  L. Jebavý,et al.  Global quality of life in patients who have undergone the hematopoietic stem cell transplantation: finding from transversal and retrospective study. , 2005, Experimental oncology.

[46]  Matthew W. Darlison,et al.  Standards for the Clinical Care of Children and Adults with Thalassaemia in the UK , 2005 .

[47]  Thomas J. Smith,et al.  Assessment of Optimal Size and Composition of the U.S. National Registry of Hematopoietic Stem Cell Donors , 2004, Transplantation.

[48]  Z. Fridlender,et al.  Myocardial infarction in a patient with β‐thalassemia major: First report , 2004, American journal of hematology.

[49]  C. Eiser,et al.  A review of measures of quality of life for children with chronic illness , 2001, Archives of disease in childhood.

[50]  P. Dolan,et al.  Modeling valuations for EuroQol health states. , 1997, Medical care.

[51]  N. Freemantle.  Cost-Effectiveness in Health and Medicine , 1997 .

[52]  D A Revicki,et al.  Relationship between health utility and psychometric health status measures. , 1992, Medical care.